SY 4835
Alternative Names: SY-4835Latest Information Update: 28 Jul 2024
At a glance
- Originator Shouyao Holdings
- Class Antineoplastics; Small molecules
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 28 Jun 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05291182)